{"ticker": {"uuid": "8b163fdd-848f-4c1a-a72f-3a391c70131b", "symbol": "RAPP", "name": "Rapport Therapeutics, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "RAPP Reiterates by BTIG -- Price Target Maintained at $65.00", "summary": "BTIG has reiterated a 'Buy' rating for Rapport Therapeutics (RAPP), maintaining its price target at $65.00, suggesting significant upside potential from its current price of $39.92. Despite this analyst confidence, the company has a low GF Score\u2122 of 14/100, indicating weaknesses,", "url": "https://www.gurufocus.com/news/8961951/rapp-reiterates-by-btig-price-target-maintained-at-6500", "source_name": "GuruFocus", "published_at": "2026-07-16T11:09:50", "published_display": "16 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-16T05:52:27+00:00", "published_display": "16 Jul 2026 05:52", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics CEO Ceesay Abraham sells $328,436 in stock By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQUFpKZm81enpWOTl0NW52LVp1Y3VWQ1cxMGx0b25sNW5tOHJOdVlDOHRQU3doSXhMNW4wa0tUVVg4R2VteWt0QURRNDRzakxWUmVLTVdjTnlQRmg1UUJHaEZsRjBuYlBHSXVWQmhkczFjRTlGYW9sTkRncVBrTkhpOEsxcXZCN3pXOHdWa2MwTGc1Qml3Yld1V2ZlaTA1YzNaREZzc04wVElIb2dvbC1FS2xpVHRVcV9VU2hFZjJGbw?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T21:34:49+00:00", "published_display": "15 Jul 2026 21:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Rapport Therapeutics Inc For: 15 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPUl9lSHhDbGJOU2xrellYMTkxMUlPZnpXTGFSd3hDUmZUcTZvM1d2djloMkFPWThrU2NNLTh1elp0eC1FZnp3aVJwSVNpMnBFajFXVjVPYzFKRW1rekdMYzlSbHBlWnVKTi1DTmgxb3NYVFdwS3F4cTNPN0hDRnM5NEZiTmQtd0QtV2NrUVJvdzhXR0c0elllNzk0MDJ4MHBCUm5Mb3d1WQ?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T21:09:16+00:00", "published_display": "15 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics CEO Ceesay Abraham sells $328,436 in stock", "summary": "Rapport Therapeutics CEO Ceesay Abraham sold shares worth $328,436 on July 14, 2026, executed under a Rule 10b5-1 trading plan. Despite the sale, Abraham retains significant direct and indirect ownership in the company, which has seen a 188% return over the past year. Analyst fir", "url": "https://www.investing.com/news/insider-trading-news/rapport-therapeutics-ceo-ceesay-abraham-sells-328436-in-stock-93CH-4794228", "source_name": "Investing.com", "published_at": "2026-07-15T20:50:49", "published_display": "15 Jul 2026 20:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABCL Stock Price and Chart \u2014 NASDAQ:ABCL", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5OcWdVN0loMWtOSUN0Vnc3dzZhR3o5cEYtNWlzOFQ1TXhXQ2VJOHNlQ1lNX29vdmtmb0RxVXl0aFB3VlRDUHZ5REVsYl9ReDl4MGxpNDltSE1JbXN2?oc=5", "source_name": "TradingView", "published_at": "2026-07-14T03:36:05+00:00", "published_display": "14 Jul 2026 03:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Rapport Therapeutics, Inc. \u2013 NASDAQ:RAPP", "summary": "This article provides a financial snapshot for Rapport Therapeutics, Inc. (NASDAQ: RAPP), focusing on its enterprise value to revenue forward metric. It appears to be a stub or a data placeholder from TradingView, indicating that specific financial data for this metric might be d", "url": "https://www.tradingview.com/symbols/NASDAQ-RAPP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T19:12:43", "published_display": "13 Jul 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?", "summary": "", "url": "https://finance.yahoo.com/m/edd0f797-63ca-331b-966d-798e85d4b29e/what-does-the-sale-of-rapport.html", "source_name": "Motley Fool", "published_at": "2026-07-12T23:53:01+00:00", "published_display": "12 Jul 2026 23:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the RAPP Inflection", "summary": "This article analyzes Rapport Therapeutics Inc. (NASDAQ: RAPP), highlighting a strong overweight bias due to positive sentiment across all time horizons. It details a compelling 57.8:1 risk-reward setup targeting a 16.2% gain, along with three distinct AI-generated trading strate", "url": "https://news.stocktradersdaily.com/news_release/90/Responsive_Playbooks_and_the_RAPP_Inflection_071226092402_1783905842.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T21:24:00", "published_display": "12 Jul 2026 21:24", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics (RAPP) Q1 2026 earnings summary", "summary": "Rapport Therapeutics (RAPP) reported its Q1 2026 earnings, highlighting $20.0 million in collaboration revenue from a new license agreement for RAP-219 in Greater China. The company's net loss narrowed to $19.9 million, and its lead candidate RAP-219 showed positive Phase 2a resu", "url": "https://quartr.com/events/rapport-therapeutics-inc-rapp-q1-2026_F38XHnbl", "source_name": "Quartr", "published_at": "2026-07-10T20:10:34", "published_display": "10 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics (RAPP) TD Cowen 45th Annual Healthcare Conference Summary", "summary": "Rapport Therapeutics (RAPP) presented at the TD Cowen 45th Annual Healthcare Conference, highlighting its precision neuroscience focus with lead program RAP-219. This drug targets TARP gamma-8 for focal onset seizures, showing a favorable safety profile and ongoing Phase 2A trial", "url": "https://quartr.com/events/rapport-therapeutics-inc-rapp-td-cowen-45th-annual-healthcare-conference_F38XEWx2", "source_name": "Quartr", "published_at": "2026-07-10T15:10:09", "published_display": "10 Jul 2026 15:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4x P B For Rapport Therapeutics (RAPP) After Russell Index Additions Looks Pricey", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics (RAPP) Stifel 2025 Healthcare Conference Summary", "summary": "This article summarizes Rapport Therapeutics' (RAPP) presentation at the Stifel 2025 Healthcare Conference, highlighting its precision neuroscience approach and lead program, RAP-219. The program shows promise in epilepsy with robust efficacy and tolerability in phase 2 studies, ", "url": "https://quartr.com/events/rapport-therapeutics-inc-rapp-stifel-2025-healthcare-conference_F38XHRt1", "source_name": "Quartr", "published_at": "2026-07-03T19:42:19", "published_display": "03 Jul 2026 19:42", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Broad Russell Index Additions At Rapport Therapeutics (RAPP) Have Changed Its Investment Story", "summary": "Rapport Therapeutics (RAPP) was recently added to several Russell growth and small-cap indices, including the Russell 2000 Growth and Russell 3000 Growth. While this inclusion will improve institutional visibility and liquidity, it doesn't alter the core clinical, funding, or exe", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/how-broad-russell-index-additions-at-rapport-therapeutics-ra", "source_name": "Simply Wall Street", "published_at": "2026-07-03T16:46:16", "published_display": "03 Jul 2026 16:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Cheryl Gault Sells 10,000 Shares of Rapport Therap", "summary": "Cheryl Gault, COO of Rapport Therapeutics Inc's subsidiary, sold 10,000 shares of RAPP on June 30, 2026, reducing her holdings to 149,914 shares. This transaction is part of a larger trend of insider selling at Rapport Therapeutics, with 30 insider sells against 3 buys over the p", "url": "https://www.gurufocus.com/news/8941889/insider-sell-cheryl-gault-sells-10000-shares-of-rapport-therapeutics-inc-rapp", "source_name": "GuruFocus", "published_at": "2026-07-02T18:09:48", "published_display": "02 Jul 2026 18:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics (RAPP) COO sells 10,000 shares in pre-set 10b5-1 trades", "summary": "Rapport Therapeutics' Chief Operating Officer, Cheryl Gault, sold 10,000 shares of common stock on June 30, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan at weighted average prices between approximately $40 and $43 per share, totaling around", "url": "https://www.stocktitan.net/sec-filings/RAPP/form-4-rapport-therapeutics-inc-insider-trading-activity-44a6f8c49adf.html", "source_name": "Stock Titan", "published_at": "2026-07-02T17:40:16", "published_display": "02 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RAPP - Rapport Therapeutics Inc Short Interest", "summary": "This article provides a detailed overview of Rapport Therapeutics Inc. (RAPP) financial data, stock performance, and short interest as of July 2nd. It includes key metrics such as market cap, income, sales, various ratios, EPS estimates, and insider/institutional ownership percen", "url": "https://finviz.com/stock?t=RAPP&b=2&p=d&ty=si", "source_name": "Finviz", "published_at": "2026-07-02T13:39:18", "published_display": "02 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding the Setup: (RAPP) and Scalable Risk", "summary": "This article analyzes Rapport Therapeutics Inc. (NASDAQ: RAPP), highlighting strong sentiment across all time horizons supporting an overweight bias. It details an exceptional 57.5:1 risk-reward setup, targeting a 16.3% gain against 0.3% risk. The analysis includes three AI-gener", "url": "https://news.stocktradersdaily.com/news_release/98/Understanding_the_Setup:_RAPP_and_Scalable_Risk_070126081602_1782951362.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-01T20:16:00", "published_display": "01 Jul 2026 20:16", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics (RAPP) CEO sells 8,220 shares under Rule 10b5-1 plans", "summary": "Rapport Therapeutics (RAPP) CEO Abraham Ceesay sold 8,220 shares of common stock on June 29, 2026, through pre-arranged Rule 10b5-1 trading plans. The shares were sold in two transactions at weighted average prices of $39.77 and $40.34 per share. Following these sales, Ceesay dir", "url": "https://www.stocktitan.net/sec-filings/RAPP/form-4-rapport-therapeutics-inc-insider-trading-activity-80743c135626.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:32", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Rapport Therapeutics, Inc. SEC Filing", "summary": "This SEC filing ([144] Form 144) for Rapport Therapeutics, Inc. (RAPP) details a proposed sale of 10,000 shares of common stock with an aggregate market value of $403,900.00. The shares were acquired as founders' shares on September 5, 2024, and are to be sold through Morgan Stan", "url": "https://www.stocktitan.net/sec-filings/RAPP/144-rapport-therapeutics-inc-sec-filing-f8732d8d9000.html", "source_name": "Stock Titan", "published_at": "2026-07-01T07:39:57", "published_display": "01 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics stock hits all-time high at 42.36 USD By Investing.com", "summary": "Rapport Therapeutics Inc. stock has reached an all-time high of $42.36, reflecting a significant 1-year increase of 266.84% and market capitalization of $1.93 billion. This milestone is supported by strong analyst confidence, with multiple firms reiterating \"Buy\" or \"Outperform\" ", "url": "https://m.za.investing.com/news/stock-market-news/rapport-therapeutics-stock-hits-alltime-high-at-4236-usd-93CH-4350252?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-01T04:39:57", "published_display": "01 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 85, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics stock hits all-time high at 42.36 USD", "summary": "Rapport Therapeutics Inc.'s stock has reached an all-time high of $42.36, showcasing significant investor confidence with a 266.84% increase over the last year and a market capitalization of $1.93 billion. This rise is supported by multiple analyst upgrades and positive sentiment", "url": "https://www.investing.com/news/company-news/rapport-therapeutics-stock-hits-alltime-high-at-4236-usd-93CH-4768343", "source_name": "Investing.com", "published_at": "2026-06-30T11:48:00", "published_display": "30 Jun 2026 11:48", "sentiment": "positive", "sentiment_pct": 92, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to Russell Microcap Growth Benchmark Index", "summary": "Rapport Therapeutics, Inc. (NasdaqGM:RAPP) has been added to the Russell Microcap Growth Benchmark Index. This inclusion is part of several recent additions to various Russell indices, reflecting the company's growing presence in the market. The clinical-stage biotechnology compa", "url": "https://www.marketscreener.com/news/rapport-therapeutics-inc-nasdaqgm-rapp-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08df225", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:10:47", "published_display": "29 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 2000 Growth Benchmark", "summary": "Rapport Therapeutics, Inc. (NasdaqGM: RAPP) has been added to the Russell 2000 Growth Benchmark. The company, a clinical-stage biotechnology firm, focuses on developing precision small-molecule medicines for neurological and psychiatric disorders, utilizing its RAP technology pla", "url": "https://www.marketscreener.com/news/rapport-therapeutics-inc-nasdaqgm-rapp-added-to-russell-2000-growth-benchmark-ce7f5fded18df221", "source_name": "marketscreener.com", "published_at": "2026-06-29T07:32:00", "published_display": "29 Jun 2026 07:32", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 3000E Growth Benchmark", "summary": "Rapport Therapeutics, Inc. (NasdaqGM: RAPP) has been added to the Russell 3000E Growth Benchmark. This news follows several other recent additions to various Russell indices, underscoring the company's growing market presence. Rapport Therapeutics is a clinical-stage biotechnolog", "url": "https://www.marketscreener.com/news/rapport-therapeutics-inc-nasdaqgm-rapp-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8cf221", "source_name": "marketscreener.com", "published_at": "2026-06-29T05:07:00", "published_display": "29 Jun 2026 05:07", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics, Inc. Actuals & Estimates (NASDAQ:RAPP)", "summary": "This article provides an overview of Rapport Therapeutics, Inc. (NASDAQ:RAPP) stock, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates for the company, covering earnings, revenue, and market capitalization,", "url": "https://www.tradingview.com/symbols/NASDAQ-RAPP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:39:32", "published_display": "26 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RAPP Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Rapport Therapeutics, Inc. (RAPP) stock, including price targets and analyst ratings. It details the company's current stock price, historical performance, market capitalization, and upcoming earnings report. The piece also addresses frequentl", "url": "https://www.tradingview.com/symbols/NASDAQ-RAPP/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:11:57", "published_display": "25 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Partners Initiates Rapport Therapeutics at Outperform With $52 Price Target", "summary": "Leerink Partners has initiated coverage on Rapport Therapeutics with an Outperform rating and a $52 price target. This announcement highlights positive analyst sentiment for the biotechnology company, which focuses on developing precision medicines for neurological and psychiatri", "url": "https://www.marketscreener.com/news/leerink-partners-initiates-rapport-therapeutics-at-outperform-with-52-price-target-ce7f5fdbdf8dff2c", "source_name": "marketscreener.com", "published_at": "2026-06-24T11:40:36", "published_display": "24 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics Inc (RAPP) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Rapport Therapeutics Inc (RAPP), detailing its current stock price, market capitalization, and various technical indicators. It presents a summary of buy, sell, and neutral signals based on indicators like MACD, RSI, and moving averag", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rapp/technical", "source_name": "TradingKey", "published_at": "2026-06-24T02:10:57", "published_display": "24 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (RAPP) That Institutions Follow", "summary": "This article analyzes Rapport Therapeutics Inc. (NASDAQ: RAPP), highlighting positive near-term sentiment but potential mid-term weakness within a strong long-term context. It details institutional trading strategies including long, breakout, and short setups, with specific entry", "url": "https://news.stocktradersdaily.com/news_release/101/The_Technical_Signals_Behind_RAPP_That_Institutions_Follow_062026070402_1781996642.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-20T19:04:00", "published_display": "20 Jun 2026 19:04", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics Inc (RAPP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Rapport Therapeutics Inc (RAPP), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It lists the current stock price and market ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rapp/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T00:39:06", "published_display": "19 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics Inc (RAPP) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Rapport Therapeutics Inc (RAPP) focusing on its dividend history and stock splits. It states that the company has not distributed any dividends over the past five years and has no recorded stock split events. The article also includes current ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rapp/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T22:39:06", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics Inc (RAPP) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Rapport Therapeutics Inc (RAPP), focusing on its profitability and balance sheet. While the company's stock price, market cap, and P/E ratio are provided, the detailed financial metrics for cash and cash equivalents, total assets, lia", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rapp/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T06:10:20", "published_display": "18 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPVkc0TzA1ODRZNlJxdS0xbzVSMUFUQlR0QXNsWkhRSzctNjZPemlXUmh0V0RJVlhMQUM5Rl9jejVjclNXNW9JeWUtVzBxWjU2Zk1Cd19XS3dtOVVQYy1HMXBJNXpReWwyRXJNTjVzbUdZc3lnSjZ1OXhzN185d0RKaHlwbzVZOU84dkEtLWFWQy1mQlFLQWl2ajkxUFpOeHVi?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNMEU4SnVvbWE2YkhSTlNTcGd0UUhiOUo1LWlHTVN3LVJSb1B6SUd5cDBUcE1DbFVRSFJCLWx5MDVQWFcyRmpmWmZTaGFnazJxdW93dW9BQTAwTW9aaF82UW1ISGp3ZHlhQmNKVy1kb1p0ZnliMmFaX21lT1NDam5PM3IxRTh6NzRicm9DZlJyc1l0RjJVVU5Qd2tvZmZiNENaYUVWOF82dw?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Raises its Price Target on Rapport Therapeutics (RAPP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNMC1acU1aQ1lQMVpGOWRJeDVDWjJfOGRHbjNVQ1dJMnNhNmlPMUhPNXlYdU9KQVAzWFFPYzVzTFlKREhyckJoTUtjb0VhWjRuTUw5NGYyZG5PRFEzb0JHOEFVZ0JOcUNRYlJsbW9ZR01RYmhMUWVtNUo3QVM2Z21SZk5vUVlyejdkdDZIQWhNWG5SVTdIbzlUYlhRZXVvSGVkSHBJ?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rapport-therapeutics-participate-jefferies-global-200500073.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T20:05:00+00:00", "published_display": "20 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Third Rock Ventures v sells $5.38m in Rapport Therapeutics stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOd19mUzh0ajVoVEh6aS15dkkxcDhtbU9fT0xPTi1yUF9FZnB2TmlWMktISzJOWVhiR0QyTm5OZ05IcmM4QU0zdHY3LU9rOXNmUWF5Qzc1RnB5bmVQYWpyUm9leFRMOUFiSjlVMWY5Q3oxSFptbFRIZ3BVb2w0aHdBREJhOU02RkhnNFUwdm9oeDFhSGxSMXJZcnR4WURIQnIzdmZzNXl6SmJYX2NUTmJLSG5CNXZVMlVIMEl5MEh2QXQ1cWhpVFE?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQV0MtcThQTWR3TjFtaU14Smh3bnA0bVBHZWx6Q2FQSURYRUM5U0otVXdYOVhkMUhwNWQzZm9tRGl5aG9Yd0pZZ3p1SFJLR3pPVkVCVTNwUV9aeG5hME1reXVCaGZrZjVVOWt2NDdKTWVPR1JPOFF6Snp4a003V0dFaXBPTXIzZWJSOHRZTHdDR0lsMlVuSnpud3otR1c2YjVmNUZUckM4Y01tNkQ5NFhpUWpTczROd09sUEpHY3VDZ1Y5YW9wbHA5ZE5TVS1YRVRGbmNtNFZ6ajlEcVk1dkxLejhaNjBTVDBEOVR4dFRGWEw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPTDJ3MVhmSk1LRzJXMjgza3lsSEVIVFN1MElOandIeFNjVmI1TWFaWjVkQ0xDX1ZqZmtnb0pJQmJ0TE9Xc0QyZllrazZUaFN0Vk8xcWM1a3BWSzc4MWFoOElRNGtJWnJWTDBPa080VTJfZ0xSbVYxTVZIVXJ3blQzUkxZdzA5eTdhNzNpdHdrLXNsVUcxeWVNcUpEUzlYbkVpVExTZmJHbG5EZw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics Insiders Added US$1.61m Of Stock To Their Holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPZUFtbUk2WTFVTEpRd2lKaXcyWTNWc3ZEUTZ4aEVzOEVyUF9iMHBacWFLZWtRWVhKYURreFlkQnEwbDhiTUFwUExLSXR3bnBTaDBtUGo1VjNoVkFjb1FCWF9ZS1JRSDZIeXp0TkkyQVZhVnV6eURudHpFVnZBMlBsZWRWQ2NUc3NHVnhSbmVfUDE2VDZ4SkJEbWQ3Q1VQYWhKM1d3Q3p3?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPZE01OE9WdVk0SFMtUjQwM0trbVFCQ3dYUXk4WWJVRkZIeVg0aEMza2dQWE9INWtpak9pX3BGVUdZZmdZUnN2MVJmdkFYRVM5QTJobHFhbmdnbGRUWjdXczdmVUpaQ21IeDRlX3VKTXZla3JVMEN3MjRiWVVSRkhJQjBJUGw1cXZWcE04NXpNbXJDR0IweGUtYWo3cVVqZFZhd08xcnhRM09PcEQtMGtLaFlXVms0WEI4SktzLVNhTTlVZG9LOUZyMVVqQ3VkUkpKaVdzdHBCWTM?oc=5", "source_name": "The Motley Fool", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seizures stayed sharply lower after treatment stopped in Rapport trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQeUZTS2NCT0oydENvX3JaZk9GT0hjY3JqOTdIWG9hdXQ5Ym5rbFFzcGFkandBOFVQcjVTTUl2VTdOanVhMjc2c2tadnRnak9jYi11Nm1weWtfOVBlNE1TR1hFM0x2MC00UzdUTXlCRzFsR1NSMXprQ1JVLWNyeXN1dFk3YmhFX1Y4b2F6Vm5vdW1la0kxbXRYZnNhR2xxZW50aTBYa1VGVjgtR1VhSGJ3U2JtVDJMdnA1dU5KOEZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "RAPP Reiterates by BTIG -- Price Target Maintained at $65.00", "summary": "BTIG has reiterated a 'Buy' rating for Rapport Therapeutics (RAPP), maintaining its price target at $65.00, suggesting significant upside potential from its current price of $39.92. Despite this analyst confidence, the company has a low GF Score\u2122 of 14/100, indicating weaknesses,", "url": "https://www.gurufocus.com/news/8961951/rapp-reiterates-by-btig-price-target-maintained-at-6500", "source_name": "GuruFocus", "published_at": "2026-07-16T11:09:50", "published_display": "16 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-16T05:52:27+00:00", "published_display": "16 Jul 2026 05:52", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics CEO Ceesay Abraham sells $328,436 in stock By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQUFpKZm81enpWOTl0NW52LVp1Y3VWQ1cxMGx0b25sNW5tOHJOdVlDOHRQU3doSXhMNW4wa0tUVVg4R2VteWt0QURRNDRzakxWUmVLTVdjTnlQRmg1UUJHaEZsRjBuYlBHSXVWQmhkczFjRTlGYW9sTkRncVBrTkhpOEsxcXZCN3pXOHdWa2MwTGc1Qml3Yld1V2ZlaTA1YzNaREZzc04wVElIb2dvbC1FS2xpVHRVcV9VU2hFZjJGbw?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T21:34:49+00:00", "published_display": "15 Jul 2026 21:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Rapport Therapeutics Inc For: 15 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPUl9lSHhDbGJOU2xrellYMTkxMUlPZnpXTGFSd3hDUmZUcTZvM1d2djloMkFPWThrU2NNLTh1elp0eC1FZnp3aVJwSVNpMnBFajFXVjVPYzFKRW1rekdMYzlSbHBlWnVKTi1DTmgxb3NYVFdwS3F4cTNPN0hDRnM5NEZiTmQtd0QtV2NrUVJvdzhXR0c0elllNzk0MDJ4MHBCUm5Mb3d1WQ?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T21:09:16+00:00", "published_display": "15 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics CEO Ceesay Abraham sells $328,436 in stock", "summary": "Rapport Therapeutics CEO Ceesay Abraham sold shares worth $328,436 on July 14, 2026, executed under a Rule 10b5-1 trading plan. Despite the sale, Abraham retains significant direct and indirect ownership in the company, which has seen a 188% return over the past year. Analyst fir", "url": "https://www.investing.com/news/insider-trading-news/rapport-therapeutics-ceo-ceesay-abraham-sells-328436-in-stock-93CH-4794228", "source_name": "Investing.com", "published_at": "2026-07-15T20:50:49", "published_display": "15 Jul 2026 20:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABCL Stock Price and Chart \u2014 NASDAQ:ABCL", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5OcWdVN0loMWtOSUN0Vnc3dzZhR3o5cEYtNWlzOFQ1TXhXQ2VJOHNlQ1lNX29vdmtmb0RxVXl0aFB3VlRDUHZ5REVsYl9ReDl4MGxpNDltSE1JbXN2?oc=5", "source_name": "TradingView", "published_at": "2026-07-14T03:36:05+00:00", "published_display": "14 Jul 2026 03:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Rapport Therapeutics, Inc. \u2013 NASDAQ:RAPP", "summary": "This article provides a financial snapshot for Rapport Therapeutics, Inc. (NASDAQ: RAPP), focusing on its enterprise value to revenue forward metric. It appears to be a stub or a data placeholder from TradingView, indicating that specific financial data for this metric might be d", "url": "https://www.tradingview.com/symbols/NASDAQ-RAPP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T19:12:43", "published_display": "13 Jul 2026 19:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?", "summary": "", "url": "https://finance.yahoo.com/m/edd0f797-63ca-331b-966d-798e85d4b29e/what-does-the-sale-of-rapport.html", "source_name": "Motley Fool", "published_at": "2026-07-12T23:53:01+00:00", "published_display": "12 Jul 2026 23:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the RAPP Inflection", "summary": "This article analyzes Rapport Therapeutics Inc. (NASDAQ: RAPP), highlighting a strong overweight bias due to positive sentiment across all time horizons. It details a compelling 57.8:1 risk-reward setup targeting a 16.2% gain, along with three distinct AI-generated trading strate", "url": "https://news.stocktradersdaily.com/news_release/90/Responsive_Playbooks_and_the_RAPP_Inflection_071226092402_1783905842.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T21:24:00", "published_display": "12 Jul 2026 21:24", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics (RAPP) Q1 2026 earnings summary", "summary": "Rapport Therapeutics (RAPP) reported its Q1 2026 earnings, highlighting $20.0 million in collaboration revenue from a new license agreement for RAP-219 in Greater China. The company's net loss narrowed to $19.9 million, and its lead candidate RAP-219 showed positive Phase 2a resu", "url": "https://quartr.com/events/rapport-therapeutics-inc-rapp-q1-2026_F38XHnbl", "source_name": "Quartr", "published_at": "2026-07-10T20:10:34", "published_display": "10 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics (RAPP) TD Cowen 45th Annual Healthcare Conference Summary", "summary": "Rapport Therapeutics (RAPP) presented at the TD Cowen 45th Annual Healthcare Conference, highlighting its precision neuroscience focus with lead program RAP-219. This drug targets TARP gamma-8 for focal onset seizures, showing a favorable safety profile and ongoing Phase 2A trial", "url": "https://quartr.com/events/rapport-therapeutics-inc-rapp-td-cowen-45th-annual-healthcare-conference_F38XEWx2", "source_name": "Quartr", "published_at": "2026-07-10T15:10:09", "published_display": "10 Jul 2026 15:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4x P B For Rapport Therapeutics (RAPP) After Russell Index Additions Looks Pricey", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics (RAPP) Stifel 2025 Healthcare Conference Summary", "summary": "This article summarizes Rapport Therapeutics' (RAPP) presentation at the Stifel 2025 Healthcare Conference, highlighting its precision neuroscience approach and lead program, RAP-219. The program shows promise in epilepsy with robust efficacy and tolerability in phase 2 studies, ", "url": "https://quartr.com/events/rapport-therapeutics-inc-rapp-stifel-2025-healthcare-conference_F38XHRt1", "source_name": "Quartr", "published_at": "2026-07-03T19:42:19", "published_display": "03 Jul 2026 19:42", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Broad Russell Index Additions At Rapport Therapeutics (RAPP) Have Changed Its Investment Story", "summary": "Rapport Therapeutics (RAPP) was recently added to several Russell growth and small-cap indices, including the Russell 2000 Growth and Russell 3000 Growth. While this inclusion will improve institutional visibility and liquidity, it doesn't alter the core clinical, funding, or exe", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/how-broad-russell-index-additions-at-rapport-therapeutics-ra", "source_name": "Simply Wall Street", "published_at": "2026-07-03T16:46:16", "published_display": "03 Jul 2026 16:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Cheryl Gault Sells 10,000 Shares of Rapport Therap", "summary": "Cheryl Gault, COO of Rapport Therapeutics Inc's subsidiary, sold 10,000 shares of RAPP on June 30, 2026, reducing her holdings to 149,914 shares. This transaction is part of a larger trend of insider selling at Rapport Therapeutics, with 30 insider sells against 3 buys over the p", "url": "https://www.gurufocus.com/news/8941889/insider-sell-cheryl-gault-sells-10000-shares-of-rapport-therapeutics-inc-rapp", "source_name": "GuruFocus", "published_at": "2026-07-02T18:09:48", "published_display": "02 Jul 2026 18:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics (RAPP) COO sells 10,000 shares in pre-set 10b5-1 trades", "summary": "Rapport Therapeutics' Chief Operating Officer, Cheryl Gault, sold 10,000 shares of common stock on June 30, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan at weighted average prices between approximately $40 and $43 per share, totaling around", "url": "https://www.stocktitan.net/sec-filings/RAPP/form-4-rapport-therapeutics-inc-insider-trading-activity-44a6f8c49adf.html", "source_name": "Stock Titan", "published_at": "2026-07-02T17:40:16", "published_display": "02 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RAPP - Rapport Therapeutics Inc Short Interest", "summary": "This article provides a detailed overview of Rapport Therapeutics Inc. (RAPP) financial data, stock performance, and short interest as of July 2nd. It includes key metrics such as market cap, income, sales, various ratios, EPS estimates, and insider/institutional ownership percen", "url": "https://finviz.com/stock?t=RAPP&b=2&p=d&ty=si", "source_name": "Finviz", "published_at": "2026-07-02T13:39:18", "published_display": "02 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding the Setup: (RAPP) and Scalable Risk", "summary": "This article analyzes Rapport Therapeutics Inc. (NASDAQ: RAPP), highlighting strong sentiment across all time horizons supporting an overweight bias. It details an exceptional 57.5:1 risk-reward setup, targeting a 16.3% gain against 0.3% risk. The analysis includes three AI-gener", "url": "https://news.stocktradersdaily.com/news_release/98/Understanding_the_Setup:_RAPP_and_Scalable_Risk_070126081602_1782951362.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-01T20:16:00", "published_display": "01 Jul 2026 20:16", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics (RAPP) CEO sells 8,220 shares under Rule 10b5-1 plans", "summary": "Rapport Therapeutics (RAPP) CEO Abraham Ceesay sold 8,220 shares of common stock on June 29, 2026, through pre-arranged Rule 10b5-1 trading plans. The shares were sold in two transactions at weighted average prices of $39.77 and $40.34 per share. Following these sales, Ceesay dir", "url": "https://www.stocktitan.net/sec-filings/RAPP/form-4-rapport-therapeutics-inc-insider-trading-activity-80743c135626.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:32", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Rapport Therapeutics, Inc. SEC Filing", "summary": "This SEC filing ([144] Form 144) for Rapport Therapeutics, Inc. (RAPP) details a proposed sale of 10,000 shares of common stock with an aggregate market value of $403,900.00. The shares were acquired as founders' shares on September 5, 2024, and are to be sold through Morgan Stan", "url": "https://www.stocktitan.net/sec-filings/RAPP/144-rapport-therapeutics-inc-sec-filing-f8732d8d9000.html", "source_name": "Stock Titan", "published_at": "2026-07-01T07:39:57", "published_display": "01 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics stock hits all-time high at 42.36 USD By Investing.com", "summary": "Rapport Therapeutics Inc. stock has reached an all-time high of $42.36, reflecting a significant 1-year increase of 266.84% and market capitalization of $1.93 billion. This milestone is supported by strong analyst confidence, with multiple firms reiterating \"Buy\" or \"Outperform\" ", "url": "https://m.za.investing.com/news/stock-market-news/rapport-therapeutics-stock-hits-alltime-high-at-4236-usd-93CH-4350252?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-01T04:39:57", "published_display": "01 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 85, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics stock hits all-time high at 42.36 USD", "summary": "Rapport Therapeutics Inc.'s stock has reached an all-time high of $42.36, showcasing significant investor confidence with a 266.84% increase over the last year and a market capitalization of $1.93 billion. This rise is supported by multiple analyst upgrades and positive sentiment", "url": "https://www.investing.com/news/company-news/rapport-therapeutics-stock-hits-alltime-high-at-4236-usd-93CH-4768343", "source_name": "Investing.com", "published_at": "2026-06-30T11:48:00", "published_display": "30 Jun 2026 11:48", "sentiment": "positive", "sentiment_pct": 92, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics, Inc.(NasdaqGM:RAPP) added to Russell Microcap Growth Benchmark Index", "summary": "Rapport Therapeutics, Inc. (NasdaqGM:RAPP) has been added to the Russell Microcap Growth Benchmark Index. This inclusion is part of several recent additions to various Russell indices, reflecting the company's growing presence in the market. The clinical-stage biotechnology compa", "url": "https://www.marketscreener.com/news/rapport-therapeutics-inc-nasdaqgm-rapp-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08df225", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:10:47", "published_display": "29 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 2000 Growth Benchmark", "summary": "Rapport Therapeutics, Inc. (NasdaqGM: RAPP) has been added to the Russell 2000 Growth Benchmark. The company, a clinical-stage biotechnology firm, focuses on developing precision small-molecule medicines for neurological and psychiatric disorders, utilizing its RAP technology pla", "url": "https://www.marketscreener.com/news/rapport-therapeutics-inc-nasdaqgm-rapp-added-to-russell-2000-growth-benchmark-ce7f5fded18df221", "source_name": "marketscreener.com", "published_at": "2026-06-29T07:32:00", "published_display": "29 Jun 2026 07:32", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics, Inc.(NasdaqGM: RAPP) added to Russell 3000E Growth Benchmark", "summary": "Rapport Therapeutics, Inc. (NasdaqGM: RAPP) has been added to the Russell 3000E Growth Benchmark. This news follows several other recent additions to various Russell indices, underscoring the company's growing market presence. Rapport Therapeutics is a clinical-stage biotechnolog", "url": "https://www.marketscreener.com/news/rapport-therapeutics-inc-nasdaqgm-rapp-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8cf221", "source_name": "marketscreener.com", "published_at": "2026-06-29T05:07:00", "published_display": "29 Jun 2026 05:07", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics, Inc. Actuals & Estimates (NASDAQ:RAPP)", "summary": "This article provides an overview of Rapport Therapeutics, Inc. (NASDAQ:RAPP) stock, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates for the company, covering earnings, revenue, and market capitalization,", "url": "https://www.tradingview.com/symbols/NASDAQ-RAPP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:39:32", "published_display": "26 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RAPP Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Rapport Therapeutics, Inc. (RAPP) stock, including price targets and analyst ratings. It details the company's current stock price, historical performance, market capitalization, and upcoming earnings report. The piece also addresses frequentl", "url": "https://www.tradingview.com/symbols/NASDAQ-RAPP/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:11:57", "published_display": "25 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Partners Initiates Rapport Therapeutics at Outperform With $52 Price Target", "summary": "Leerink Partners has initiated coverage on Rapport Therapeutics with an Outperform rating and a $52 price target. This announcement highlights positive analyst sentiment for the biotechnology company, which focuses on developing precision medicines for neurological and psychiatri", "url": "https://www.marketscreener.com/news/leerink-partners-initiates-rapport-therapeutics-at-outperform-with-52-price-target-ce7f5fdbdf8dff2c", "source_name": "marketscreener.com", "published_at": "2026-06-24T11:40:36", "published_display": "24 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics Inc (RAPP) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Rapport Therapeutics Inc (RAPP), detailing its current stock price, market capitalization, and various technical indicators. It presents a summary of buy, sell, and neutral signals based on indicators like MACD, RSI, and moving averag", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rapp/technical", "source_name": "TradingKey", "published_at": "2026-06-24T02:10:57", "published_display": "24 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (RAPP) That Institutions Follow", "summary": "This article analyzes Rapport Therapeutics Inc. (NASDAQ: RAPP), highlighting positive near-term sentiment but potential mid-term weakness within a strong long-term context. It details institutional trading strategies including long, breakout, and short setups, with specific entry", "url": "https://news.stocktradersdaily.com/news_release/101/The_Technical_Signals_Behind_RAPP_That_Institutions_Follow_062026070402_1781996642.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-20T19:04:00", "published_display": "20 Jun 2026 19:04", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics Inc (RAPP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Rapport Therapeutics Inc (RAPP), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It lists the current stock price and market ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rapp/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T00:39:06", "published_display": "19 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics Inc (RAPP) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Rapport Therapeutics Inc (RAPP) focusing on its dividend history and stock splits. It states that the company has not distributed any dividends over the past five years and has no recorded stock split events. The article also includes current ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rapp/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T22:39:06", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics Inc (RAPP) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Rapport Therapeutics Inc (RAPP), focusing on its profitability and balance sheet. While the company's stock price, market cap, and P/E ratio are provided, the detailed financial metrics for cash and cash equivalents, total assets, lia", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rapp/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T06:10:20", "published_display": "18 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPVkc0TzA1ODRZNlJxdS0xbzVSMUFUQlR0QXNsWkhRSzctNjZPemlXUmh0V0RJVlhMQUM5Rl9jejVjclNXNW9JeWUtVzBxWjU2Zk1Cd19XS3dtOVVQYy1HMXBJNXpReWwyRXJNTjVzbUdZc3lnSjZ1OXhzN185d0RKaHlwbzVZOU84dkEtLWFWQy1mQlFLQWl2ajkxUFpOeHVi?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNMEU4SnVvbWE2YkhSTlNTcGd0UUhiOUo1LWlHTVN3LVJSb1B6SUd5cDBUcE1DbFVRSFJCLWx5MDVQWFcyRmpmWmZTaGFnazJxdW93dW9BQTAwTW9aaF82UW1ISGp3ZHlhQmNKVy1kb1p0ZnliMmFaX21lT1NDam5PM3IxRTh6NzRicm9DZlJyc1l0RjJVVU5Qd2tvZmZiNENaYUVWOF82dw?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Raises its Price Target on Rapport Therapeutics (RAPP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNMC1acU1aQ1lQMVpGOWRJeDVDWjJfOGRHbjNVQ1dJMnNhNmlPMUhPNXlYdU9KQVAzWFFPYzVzTFlKREhyckJoTUtjb0VhWjRuTUw5NGYyZG5PRFEzb0JHOEFVZ0JOcUNRYlJsbW9ZR01RYmhMUWVtNUo3QVM2Z21SZk5vUVlyejdkdDZIQWhNWG5SVTdIbzlUYlhRZXVvSGVkSHBJ?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rapport-therapeutics-participate-jefferies-global-200500073.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T20:05:00+00:00", "published_display": "20 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Third Rock Ventures v sells $5.38m in Rapport Therapeutics stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOd19mUzh0ajVoVEh6aS15dkkxcDhtbU9fT0xPTi1yUF9FZnB2TmlWMktISzJOWVhiR0QyTm5OZ05IcmM4QU0zdHY3LU9rOXNmUWF5Qzc1RnB5bmVQYWpyUm9leFRMOUFiSjlVMWY5Q3oxSFptbFRIZ3BVb2w0aHdBREJhOU02RkhnNFUwdm9oeDFhSGxSMXJZcnR4WURIQnIzdmZzNXl6SmJYX2NUTmJLSG5CNXZVMlVIMEl5MEh2QXQ1cWhpVFE?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQV0MtcThQTWR3TjFtaU14Smh3bnA0bVBHZWx6Q2FQSURYRUM5U0otVXdYOVhkMUhwNWQzZm9tRGl5aG9Yd0pZZ3p1SFJLR3pPVkVCVTNwUV9aeG5hME1reXVCaGZrZjVVOWt2NDdKTWVPR1JPOFF6Snp4a003V0dFaXBPTXIzZWJSOHRZTHdDR0lsMlVuSnpud3otR1c2YjVmNUZUckM4Y01tNkQ5NFhpUWpTczROd09sUEpHY3VDZ1Y5YW9wbHA5ZE5TVS1YRVRGbmNtNFZ6ajlEcVk1dkxLejhaNjBTVDBEOVR4dFRGWEw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPTDJ3MVhmSk1LRzJXMjgza3lsSEVIVFN1MElOandIeFNjVmI1TWFaWjVkQ0xDX1ZqZmtnb0pJQmJ0TE9Xc0QyZllrazZUaFN0Vk8xcWM1a3BWSzc4MWFoOElRNGtJWnJWTDBPa080VTJfZ0xSbVYxTVZIVXJ3blQzUkxZdzA5eTdhNzNpdHdrLXNsVUcxeWVNcUpEUzlYbkVpVExTZmJHbG5EZw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Therapeutics Insiders Added US$1.61m Of Stock To Their Holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPZUFtbUk2WTFVTEpRd2lKaXcyWTNWc3ZEUTZ4aEVzOEVyUF9iMHBacWFLZWtRWVhKYURreFlkQnEwbDhiTUFwUExLSXR3bnBTaDBtUGo1VjNoVkFjb1FCWF9ZS1JRSDZIeXp0TkkyQVZhVnV6eURudHpFVnZBMlBsZWRWQ2NUc3NHVnhSbmVfUDE2VDZ4SkJEbWQ3Q1VQYWhKM1d3Q3p3?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxPZE01OE9WdVk0SFMtUjQwM0trbVFCQ3dYUXk4WWJVRkZIeVg0aEMza2dQWE9INWtpak9pX3BGVUdZZmdZUnN2MVJmdkFYRVM5QTJobHFhbmdnbGRUWjdXczdmVUpaQ21IeDRlX3VKTXZla3JVMEN3MjRiWVVSRkhJQjBJUGw1cXZWcE04NXpNbXJDR0IweGUtYWo3cVVqZFZhd08xcnhRM09PcEQtMGtLaFlXVms0WEI4SktzLVNhTTlVZG9LOUZyMVVqQ3VkUkpKaVdzdHBCWTM?oc=5", "source_name": "The Motley Fool", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seizures stayed sharply lower after treatment stopped in Rapport trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQeUZTS2NCT0oydENvX3JaZk9GT0hjY3JqOTdIWG9hdXQ5Ym5rbFFzcGFkandBOFVQcjVTTUl2VTdOanVhMjc2c2tadnRnak9jYi11Nm1weWtfOVBlNE1TR1hFM0x2MC00UzdUTXlCRzFsR1NSMXprQ1JVLWNyeXN1dFk3YmhFX1Y4b2F6Vm5vdW1la0kxbXRYZnNhR2xxZW50aTBYa1VGVjgtR1VhSGJ3U2JtVDJMdnA1dU5KOEZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 73, "sentiment_summary": {"positive": 25, "negative": 6, "neutral": 42, "score": 58, "total": 73, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 22.7, "count": 40}, {"event": "earnings", "label": "Earnings", "weight": 11.15, "count": 21}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 25, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 41.75, "latest_week": "2026-07-10", "one_week_move": 7.1, "four_week_move": 8.7, "twelve_week_move": 5.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.541773, "market_dynamics_buy_signal": false, "relative_strength": 27.018754, "fair_value_gap": 85.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 57.4387, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.1% over one week, +8.7% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "TradingView", "count": 6}, {"label": "Stock Titan", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "Stock Traders Daily", "count": 3}, {"label": "Quartr", "count": 3}, {"label": "simplywall.st", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 65}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 40}, {"label": "Earnings", "count": 21}, {"label": "Analyst action", "count": 7}, {"label": "Balance sheet", "count": 3}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "65", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+7.1% over one week, +8.7% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "RAPP Reiterates by BTIG -- Price Target Maintained at $65.00"}], "updated_at": "2026-07-17T04:55:07.554839+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}